$SLN News

Silence Therapeutics to Participate in Three September Investor Conferences

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera

HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target